logo color s and clearside.jpg
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
June 15, 2021 07:05 ET | Clearside Biomedical, Inc.
- CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events - - Initiating Cohort 2 patient screening for 0.1 mg dose in June 2021 - ...
logo color s and clearside.jpg
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021
June 09, 2021 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
logo color s and clearside.jpg
Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021 16:05 ET | Clearside Biomedical, Inc.
- Recent New Drug Application Resubmission for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) - - Cohort 1 Data in OASIS Wet AMD Phase 1/2a Trial Expected in...
logo color s and clearside.jpg
Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting
May 10, 2021 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 10, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
logo color s and clearside.jpg
Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021
May 04, 2021 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
logo color s and clearside.jpg
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
May 03, 2021 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
logo color s and clearside.jpg
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit
April 05, 2021 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
logo color s and clearside.jpg
Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 10, 2021 16:05 ET | Clearside Biomedical, Inc.
- OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed - - Initial Safety Data from OASIS Trial Expected Mid-2021 - - Four Ongoing Internal & Partner Clinical Trials Using...
logo color s and clearside.jpg
Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
March 02, 2021 07:05 ET | Clearside Biomedical, Inc.
- Initial Safety Data from First Cohort Expected Mid-2021 - ALPHARETTA, Ga., March 02, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to...
logo color s and clearside.jpg
Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021
February 24, 2021 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...